PATENT CLAIM ANALYSIS

Application Number: 15966171
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-04
Patent Classification: ["536", "024500"]

Abstract:
MicroRNA-30 is identified as being dysregulated in adipose tissue macrophages during obesity and can be used in treatment of disease in which adipose tissue macrophage polarization dysregulation plays a part. Increased concentration of microRNA-30, e.g., via pharmaceutical delivery, can decrease the polarization of macrophages, and in particular adipose tissue macrophages, to inflammatory M1 phenotype and can decrease expression of pro-inflammatory cytokines. One or more members of the miR-30 family can be utilized in the methods. Methods can be beneficial in treatment of a large number of inflammatory diseases including obesity, diabetes, cancer, autoimmune, etc.

Claim (Index 19):
The method of  claim 17 , the microRNA-30 or the polynucleotide encoding the microRNA-30 being carried by a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 91.0
- Lexical Diversity: 1.69841
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13941214', '13526347', '14241482', '14948539', '14021825']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6154865200725946
- 35 USC 102 Novelty (BERT): 0.524843212159914
- Combined Prediction Score: 0.6064221892813266
- Mean Citation Score: 217.19312
- Max Citation Score: 255.07666
- Similarity Product: 111.2700930760926

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test